Ketamine One Engages Psychology & Counselling Services Group for IRP Health
2021年9月14日 - 8:00PM
KetamineOne Capital Limited (“Ketamine One” or the
“Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a
company focused on consolidating medical clinics and becoming a
North American leader in mental health treatments, is pleased to
announce that it has entered into an agreement with Psychology
& Counselling Services Group (“
PCSG”) to
provide psychology, therapy, dietary and other mental health
services for Ketamine One’s subsidiary, IRP Health Ltd.
(“
IRP”), as early as October of 2021.
Practicing since 2006, the PCSG team of over 35
mental health professionals have treated over 11,000 patients
through their established programs including cognitive-behavioural
therapy, dialectical-behavioural therapy, emotion-focused therapy,
pain management group therapy, and high performance and sport
psychology mental health. PCSG provides individual psychotherapy,
couple/family therapy, psychological and vocational assessments, as
well as psychoeducational assessment and intervention for children,
youth and adults.
Management Commentary
“This partnership with Ketamine One demonstrates
our commitment ensuring we are providing a full multidisciplinary
approach to Mental Health for Veterans, First Responders and all of
those suffering with Mental Health challenges,” said Keith White,
President of Clinic Operations for Ketamine One.
"It is our pleasure to partner with IRP Health
and their focus on innovation and client care. We look forward to
the opportunity to expand the reach of our mental health services,”
stated Dr. Ken Kwan, PhD, CCFT, CPsych, Executive Director and
Chief Psychologist (O, W) of PCSG.
"We are excited to partner with Dr Kwan and his
team at PCS. This collaboration will allow us to expand on our
already comprehensive rehabilitation programs and will lay the
foundation for our strategy to provide mental health services
across Ontario to Veterans and First Responders," added Steven
Inglefield, Founder and CEO of IRP.
ABOUT KETAMINE ONE
KetamineOne Capital Limited (formerly Myconic
Capital Corp.) (NEO: MEDI) is a company focused on consolidating
medical clinics and becoming a North American leader in mental
health treatments. It is working to provide the critical
infrastructure needed to develop and deliver breakthrough mental
health treatments. Currently, Ketamine One has a network of 16
clinics across North America, with plans to further consolidate the
highly fragmented industry. The recent addition of KGK Science Inc.
as the Company’s contract research division also places the company
at the forefront of premium clinical research based on its 24-year
history and extensive experience in pharmaceuticals, cannabis, and
the emerging psychedelic medicine industries. As a collective
enterprise, Ketamine One is dedicated to helping solve the growing
need for safe and accessible mental health therapy.
On behalf of:
KETAMINE ONE
“Adam Deffett”Adam Deffett, Interim CEO
For further information, please contact:
Nick Kuzyk, Investor RelationsTel:
1-844-PHONE-K1 (1-844-746-6351)Email: IR@ketamine.one Web:
www.ketamine.one Twitter: @KetamineOne
Notice Regarding Forward-Looking
Information:
This news release contains forward-looking
statements including but not limited to statements regarding the
Company’s business, assets or investments, as well other statements
that are not historical facts. Readers are cautioned not to place
undue reliance on forward-looking statements, as there can be no
assurance that the plans, intentions or expectations upon which
they are based will occur. By their nature, forward-looking
statements involve numerous assumptions, known and unknown risks
and uncertainties, both general and specific, that contribute to
the possibility that the predictions, forecasts, projections and
other forward-looking statements will not occur, which may cause
actual performance and results in future periods to differ
materially from any estimates or projections of future performance
or results expressed or implied by such forward-looking statements.
These assumptions, risks and uncertainties include, among other
things, the state of the economy in general and capital markets in
particular, investor interest in the business and prospects of the
Company.
The forward-looking statements contained in this
news release are made as of the date of this news release. Except
as required by law, the Company disclaims any intention and assumes
no obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by applicable securities law. Additionally, the
Company undertakes no obligation to comment on the expectations of,
or statements made, by third parties in respect of the matters
discussed above.
Myconic Capital (TSXV:MEDI)
過去 株価チャート
から 10 2024 まで 11 2024
Myconic Capital (TSXV:MEDI)
過去 株価チャート
から 11 2023 まで 11 2024